Page 63 - AN-1-3

Advanced Neurology Targets and medications for AVM of CNS

and functional analysis of endothelial tip cell-enriched used for the treatment of severe, refractory perilesional
genes. Blood, 116(19): 4025-4033. edema due to an arteriovenous malformation treated with
stereotactic radiosurgery. J Neurosurg. 116(5): 972-977.
https://doi.org/10.1182/blood-2010-02-270819
https://doi.org/10.3171/2012.1.JNS111627
27. Wang Y, Fei D, Vanderlaan M, et al., 2004, Biological activity
of bevacizumab, a humanized anti-VEGF antibody in vitro. 38. Tanvetyanon T, Murtagh R, Bepler G, 2009, Rupture of a
Angiogenesis, 7(4): 335-345. cerebral arteriovenous malformation in a patient treated
with bevacizumab. J Thorac Oncol, 4(2):268-269.
https://doi.org/10.1007/s10456-004-8272-2
https://doi.org/10.1097/JTO.0b013e318195a642
28. Jubb AM, Harris AL, 2010, Biomarkers to predict the clinical
efficacy of bevacizumab in cancer. Lancet Oncol, 11(12): 39. Mouchtouris N, Jabbour PM, Starke RM, et al., 2015, Biology
1172-1183. of cerebral arteriovenous malformations with a focus on
inflammation. J Cereb Blood Flow Metab, 35(2): 167-175.
https://doi.org/10.1016/S1470-2045(10)70232-1
https://doi.org/10.1038/jcbfm.2014.179
29. Karnezis TT, Davidson TM, 2012, Treatment of hereditary
hemorrhagic telangiectasia with submucosal and topical 40. Winkler EA, Kim CN, Ross JM, et al., 2022, A single-cell
bevacizumab therapy. Laryngoscope, 122(3): 495-497. atlas of the normal and malformed human brain vasculature.
Science, 375(6584): eabi7377.
https://doi.org/10.1002/lary.22501
https://doi.org/10.1126/science.abi7377
30. Simonds J, Miller F, Mandel J, et al., 2009, The effect of
bevacizumab (avastin) treatment on epistaxis in hereditary 41. Spinale FG, 2002, Matrix metalloproteinases: Regulation and
hemorrhagic telangiectasia. Laryngoscope, 119(5): 988-992. dysregulation in the failing heart. Circ Res, 90(5): 520-530.
https://doi.org/10.1002/lary.20159 https://doi.org/10.1161/01.RES.0000013290.12884.A3
31. Dupuis-Girod S, Ambrun A, Decullier E, et al., 2014, 42. Galis ZS, Khatri JJ, 2002, Matrix metalloproteinases in
ELLIPSE study: A phase 1 study evaluating the tolerance vascular remodeling and atherogenesis: The good, the bad,
of bevacizumab nasal spray in the treatment of epistaxis in and the ugly. Circ Res, 90(3):251-262.
hereditary hemorrhagic telangiectasia. MAbs, 6(3): 793-798. https://doi.org/10.1161/res.90.3.251
https://doi.org/10.4161/mabs.28025 43. Lindeman JH, Abdul-Hussien H, van Bockel JH, et al., 2009,
32. Dupuis-Girod S, Ambrun A, Decullier E, et al., 2016, Clinical trial of doxycycline for matrix metalloproteinase-9
Effect of bevacizumab nasal spray on epistaxis duration Inhibition in patients with an abdominal aneurysm:
in hereditary hemorrhagic telangectasia: A randomized Doxycycline selectively depletes aortic wall neutrophils and
clinical trial. JAMA, 316(9): 934-942. cytotoxic T cells. Circulation, 119(16): 2209-2216.
https://doi.org/10.1001/jama.2016.11387 https://doi.org/10.1161/CIRCULATIONAHA.108.806505
33. Olsen LB, Kjeldsen AD, Poulsen MK, et al., 2020, High output 44. Hashimoto T, Wen G, Lawton MT, et al., 2003, Abnormal
cardiac failure in 3 patients with hereditary hemorrhagic expression of matrix metalloproteinases and tissue inhibitors
telangiectasia and hepatic vascular malformations, of metalloproteinases in brain arteriovenous malformations.
evaluation of treatment. Orphanet J Rare Dis, 15(1): 334. Stroke, 34(4): 925-931.
https://doi.org/10.1186/s13023-020-01583-6 https://doi.org/10.1161/01.STR.0000061888.71524.DF
34. Walker EJ, Su H, Shen F, et al., 2012, Bevacizumab attenuates 45. Hashimoto T, Matsumoto MM, Li JF, et al., 2005, Suppression
VEGF-induced angiogenesis and vascular malformations in of MMP-9 by doxycycline in brain arteriovenous
the adult mouse brain. Stroke, 43(7): 1925-1930. malformations. BMC Neurol, 5(1):1.
https://doi.org/10.1186/1471-2377-5-1
https://doi.org/10.1161/STROKEAHA.111.647982
46. Frenzel T, Lee CZ, Kim H, et al., 2008, Feasibility of minocycline
35. Faughnan ME, Gossage JR, Chakinala MM, et al., 2019,
Pazopanib may reduce bleeding in hereditary hemorrhagic and doxycycline use as potential vasculostatic therapy for
telangiectasia. Angiogenesis, 22(1): 145-155. brain vascular malformations: Pilot study of adverse events
and tolerance. Cerebrovasc Dis, 25(1-2): 157-163.
https://doi.org/10.1007/s10456-018-9646-1
https://doi.org/10.1159/000113733
36. Muster R, Ko N, Smith W, et al., 2021, Proof-of-concept single-
arm trial of bevacizumab therapy for brain arteriovenous 47. Burrows PE, Mulliken JB, Fishman SJ, et al., 2009,
Pharmacological treatment of a diffuse arteriovenous
malformation. BMJ Neurol Open, 3(1): e000114.
malformation of the upper extremity in a child. J Craniofac
https://doi.org/10.1136/bmjno-2020-000114 Surg, 20 Suppl 1: 597-602.
37. Williams BJ, Park DM, Sheehan JP, 2012, Bevacizumab https://doi.org/10.1097/SCS.0b013e3181927f1e

Volume 1 Issue 3 (2022) 9 https://doi.org/10.36922/an.v1i3.211